Targeted use of hepatoprotectors for the treatment of various stages of non-alcoholic fatty liver disease (fatty degeneration of the liver according to ICD 10) and associated comorbid conditions; tables for medical use

The high prevalence of NAFLD, which correlates with metabolic syndrome, necessitates a rational choice of drugs to correct not only the stages of steatosis, steatohepatitis and fibrosis of the liver, but also its metabolic phenotypes. The original tables clearly present the possibilities of combined use of statins, fenofibrates, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, sodium-dependent glucose transporter type 2 inhibitors, glucagon-like peptide-1 receptor agonists, resmedirom, ursodesoxycholic and glycerhisinic acids and their combinations, essential phospholipids, ademetionine, ornithine aspartate, taurine, human placental hydrolysate, morpholine, silymarin, artichoke leaf extract, metformin, pioglitazone and a combined solution of succinic acid depending on the clinical situation. The confirming references are based on the “Scales for assessing the levels of reliability of evidence” approved by the Order of the Ministry of Health of the Russian Federation dated February 28, 2019 No. 103n “On Approval of the Procedure and Terms for the Development of Clinical Guidelines, Their Revision, the Standard Form of Clinical Guidelines and the Requirements for Their Structure, Composition and Scientific Validity of the Information Included in the Clinical Guidelines” (with amendments and additions).